Cargando…

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors...

Descripción completa

Detalles Bibliográficos
Autores principales: Agumadu, Vivian C, Ramphul, Kamleshun, Mejias, Stephanie G, Sonaye, Ruhi, Sombans, Shaheen, Lohana, Petras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223665/
https://www.ncbi.nlm.nih.gov/pubmed/30416896
http://dx.doi.org/10.7759/cureus.3216
_version_ 1783369439135137792
author Agumadu, Vivian C
Ramphul, Kamleshun
Mejias, Stephanie G
Sonaye, Ruhi
Sombans, Shaheen
Lohana, Petras
author_facet Agumadu, Vivian C
Ramphul, Kamleshun
Mejias, Stephanie G
Sonaye, Ruhi
Sombans, Shaheen
Lohana, Petras
author_sort Agumadu, Vivian C
collection PubMed
description Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents.
format Online
Article
Text
id pubmed-6223665
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-62236652018-11-09 A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma Agumadu, Vivian C Ramphul, Kamleshun Mejias, Stephanie G Sonaye, Ruhi Sombans, Shaheen Lohana, Petras Cureus Internal Medicine Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents. Cureus 2018-08-27 /pmc/articles/PMC6223665/ /pubmed/30416896 http://dx.doi.org/10.7759/cureus.3216 Text en Copyright © 2018, Agumadu et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Agumadu, Vivian C
Ramphul, Kamleshun
Mejias, Stephanie G
Sonaye, Ruhi
Sombans, Shaheen
Lohana, Petras
A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
title A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
title_full A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
title_fullStr A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
title_full_unstemmed A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
title_short A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma
title_sort review of three new anti-interleukin-5 monoclonal antibody therapies for severe asthma
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223665/
https://www.ncbi.nlm.nih.gov/pubmed/30416896
http://dx.doi.org/10.7759/cureus.3216
work_keys_str_mv AT agumaduvivianc areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT ramphulkamleshun areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT mejiasstephanieg areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT sonayeruhi areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT sombansshaheen areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT lohanapetras areviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT agumaduvivianc reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT ramphulkamleshun reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT mejiasstephanieg reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT sonayeruhi reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT sombansshaheen reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma
AT lohanapetras reviewofthreenewantiinterleukin5monoclonalantibodytherapiesforsevereasthma